Interim Report Q1 2021

January 1 – March 31

Financial Summary for the group

KSEK	Q1, 2021	Q1, 2020
Profit/loss before tax	-8 612	-10 197
Total assets	62 482	65 012
Earnings per share before and after dilution (SEK)	-0,15	-0,21
Cash and cash equivalents as per period end	47 268	52 877
Equity ratio as per period end	93,6%	94,7%

Significant Events

Significant events during the first quarter of 2021

- Cyxone reported first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod.

Significant events after the end of the period

- World leading rheumatology authority Professor Costantino Pitzalis collaborates with Cyxone on Rabeximod Phase 2b study.

The group was formed on 30 July 2019 when Cyxone AB formed the subsidiary Cyxone Switzerland AG. The Group's Financial reports are prepared in accordance with International Financial Reporting Standards (IFRS), as adopted by the EU. The parent company applies the Swedish Annual Accounts Act (1995: 1554) and RFR 2 Accounting for Legal Entities, as the Group applies IFRS. The interim report for the parent company has been prepared in accordance with Chapter 9 of the Swedish Annual Accounts Act, Interim Report. Details of the Group's and parent company's accounting principles under IFRS are available on Cyxone's website: cyxone.com/investorrelations/.

This is a translation of the original Swedish version of the interim report. In case of any discrepancy between this translation and the Swedish original, the latter shall prevail.

Tara Heitner, CEO
Phone: +46 (0) 70 781 88 08
E-mail: tara.heitner@cyxone.com

This information is such information as Cyxone AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 a.m. CEST on 12 May 2021.

CEO Tara Heitner comments

A new year marks new beginnings. However, in 2021 we are still navigating a global pandemic that challenges us. At the same time we've never felt a stronger incentive to do what we do in Cyxone.

"Despite these challenges, our team has done a fantastic job to progress the Covid-19 trial, finding solutions to mitigate these challenging conditions in a professional way."

Tara Heitner, CEO Cyxone AB

Rabeximod in clinical phase 2 study for Covid-19

It is almost an understatement to say that last year was a challenging one - both on an individual and a societal level. In 2020, the pandemic also led Cyxone to pivot focus when we discovered that our drug candidate Rabeximod, otherwise tested as a treatment for rheumatoid arthritis, could have a positive effect on patients with moderate Covid-19. We decided to roll out clinical trials in Eastern Europe, with phase 2 set out to start January 2021.

I'm pleased to say that the Covid-19 trial has now been successfully started. The challenge of running clinical trials with Covid-19 patients during the peak of the pandemic tested our capabilities as a company with new waves of the pandemic putting countries, health care systems and personnel under immense pressure at times. The recruitment of patients into our trial has been successful despite overloaded and understaffed hospitals and due to the dedication of the Cyxone team. We have been successful in recruiting patients to the trial by opening more sites and gaining approvals in more countries than planned. We have established a good interaction with principal investigators on the sites, who are very interested in enrolling patients for our phase 2 trial. The high pressure on the hospitals has underscored the need for a drug like Rabeximod to ease the burden on health care systems.

A read out of our preliminary results of Rabeximod as treatment for Covid-19 is expected by the end of Q3 2021, as originally planned. We continue discussions with potential partners to support further drug development steps and commercialization of Rabeximod.

Rabeximod for rheumatoid arthritis

As recently announced, we are very happy to have initiated a collaboration with Professor Costantino Pitzalis, a world leading expert in translational research and biopsy driven RA clinical trials. As part of the collaboration with Cyxone,

Professor Pitzalis along with a team of world-class international rheumatologists will continue to work with Cyxone on running the Phase 2b trial. The advisors have fine-tuned and optimized the design of Cyxone's next clinical phase 2b study of Rabeximod, building on the encouraging results of the phase 2a trial. Within the scope of the collaboration Cyxone will seek to include *ex vivo* studies to deepen the understanding of the mode of action and potentially expand applicability to other disease indications. Input from Prof.Pitzalis and our team of advisors has been included in the new Phase 2b clinical trial design.

We are running the next trial in collaboration with Professor Pitzalis and this provides Cyxone the opportunity to include biopsy driven endpoints, highlighting the action of Rabeximod on immune cells in the joint and providing key biomarkers as early predictors of therapeutic efficacy.

We're very excited about the collaboration with Professor Pitzalis on the Rabeximod clinical trial and the opportunity to dive deeper into the mode of action of Rabeximod. Cyxone recently met with its rheumatology scientific advisors including Professor Pitzsalis. During the discussion on the Phase 2b clinical trial Rabeximod was highlighted as a potential ideal alternative to methotrexate as a first line therapy and the novelty of its mode of action was considered a unique selling point. Furthermore, the relevance of Rabeximod's mode of action in other indications was also discussed and this was viewed as an additional value driver. We are currently in an ongoing dialogue with potential partners on co-development or license agreement for the RA program.

T20K for multiple sclerosis and looking ahead

In the past quarter, we have progressed as planned with T20K, our drug candidate for patients with multiple sclerosis, and we continue to progress with our nonclinical studies. Work to validate the manufacturing processes with top tier CMOs, validation of biomarkers to simplify clinical development and studies for evaluating the most convenient and effective administration forms are progressing. These nonclinical studies are key components for IND submission and to ensure the greatest possibility for successful T20K clinical studies in the future.

In other news, we are also growing and strengthening the company even further including the management and development team. Cyxone is currently recruiting a head of clinical trials, ensuring continuous quality in current and future clinical trial studies.

In preparation for uplisting to the main market we have allocated resources to meet regulatory compliance in all aspects of the company for the application process.

We look forward to a productive Q2 on all our current projects, onboarding of new team members and the Covid-19 trial progression. Follow our news and information about our presence at investment events via Nasdaq First North Growth Market and the company's website: www.cyxone.com.

Tara Heitner
CEO, Cyxone

Cyxone AB

Operations

Cyxone is a Swedish biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders in convenient administration forms.

The development portfolio comprises Rabeximod, which is a clinical Phase 2 compound for rheumatoid arthritis (RA). Separately, Cyxone has initiated a Phase 2 study to investigate the benefits of Rabeximod as a treatment for Covid-19 to combat virally induced acute respiratory conditions and prevent progression to virally induced acute respiratory distress syndrome (ARDS) – the life threating condition which leads to death in these patients. The company is also developing T20K as a new treatment for multiple sclerosis (MS), based on encouraging preclinical results and a successful but limited phase 1 infusion study. More preclinical work is needed since infusion is not Cyxone's intended administration mode.

Rabeximod for rheumatoid arthritis (RA)

Cyxone is developing Rabeximod, a well-tolerated, orally available Phase 2 candidate drug with a unique mechanism of action. Rabeximod targets a subset of immune cells including inflammatory macrophages, a type of white blood cell which is the central orchestrator of the inflammatory process that causes tissue destruction in the joint and clinical symptoms in RA. Combined with the convenience of oral administration and a beneficial tolerability profile, this opens up for treatment in the early as well as later stages of the disease. It is believed to be particularly effective at onset and relapses of RA, with good potential to prevent joint destruction and progression of the disease.

Rabeximod for Covid-19

Rabeximod inhibits the release of multiple inflammatory cytokines. Inhibition of multiple cytokines rather than single cytokines is expected to yield better efficacy in Covid-19. In the case of acute respiratory disorders, the overreaction of the immune system can progress rapidly to an acute stage – ARDS, but it may be possible to prevent this progression if treated early. The favorable tolerability and safety profile of Rabeximod as well as its oral formulation make it a suitable therapy for patients with moderate Covid-19 disease severity.

T20K for multiple sclerosis (MS)

T20K is a peptide that in preclinical models reduces inflammation by reversibly modulating IL-2, a well-known player in the break-down of myelin. This potentially disease preventing mechanism-of-action is unique and T20K could thus be effective in slowing down the disease progression, preventing disease flares and postponing the need of second-line treatments. Initial preclinical data suggest that T20K has long-lasting effects and is efficacious at low doses and thus administration does not have to be frequent.

Business model

Cyxone is well positioned with three unique projects, all of which are developed to achieve important and potential value-creating milestones. The purpose of these studies is to develop drugs that benefit patients, health and the healthcare system as well as the shareholders. Cyxone's goal is to license projects to resourceful partners after Phase 2 clinical trials.

Management and Board of Directors

Cyxone's executive management team consists of experienced experts with solid knowledge in the fields of drug development, business development and financing in innovative biotech companies. Members of the Cyxone board have extensive experience of taking projects from academic research stage to publicly traded development companies, fundraising as well as negotiating license and cooperation agreements.

Aims

Cyxone's overarching aim is the development of new drugs that can make considerable improvement to the quality of life of those with severe autoimmune conditions. Today's drugs can reduce the symptoms of various conditions but are often associated with severe side-effects that limit their prolonged use. There is therefore a real need for new, effective drugs with less severe and fewer side-effects, and ideally drugs that prevent the development of autoimmune conditions, to be able to provide those affected a better quality of life.

Vision

Cyxone's vision is to develop first in class therapeutics that markedly improve the quality of life for patients based on recent understandings of the disease mechanism. The company's drugs are designed not only to be efficacious, but also more convenient for patients to take, have fewer and milder side-effects than existing treatments, and well-suited for long-term treatments. By achieving this Cyxone offers patients the opportunity to take control of the disease, and thus their lives.

Financial information

The Group

Comments on the Group's results for the period January - March 2021

Operating income amounted to 0,1 MSEK (0). The operating cost amounted to 8.7 MSEK (10.1) The overall loss for the group was 8.6 MSEK (loss:10.2).

Cash flow, liquidity and financial position, Group, for the period January - March 2021

Cash and cash equivalents at the end of the period amounted to 47.3 MSEK, compared with 52.9 MSEK at the end of March 2020. Total Equity amounts to 58.5 MSEK (61.6).

Cash flow for the period was -9.1 MSEK (9.0), of which cash flow from operating activities amounted to a -9.1 MSEK (-9.0).

Cash flow from investments amounted to 0.0 MSEK (0.0). Cash flow from financing activities amounted to 0.0 MSEK (0.0).

Investments

Investments in tangible fixed assets amounted to 0.0 MSEK (0.0).

Parent Company

Comments on the Parent Company's results and financial position for the period January - March 2021

Operating income amounted to 50 MSEK (0) and operating cost to 8.6 MSEK (10.1). The Parent Company's operating loss for the period was 8.6 MSEK (loss: 10.1).

Net financial cost amounted to 0.0 MSEK (loss: 0.1) and the loss after financial items was 8.6 MSEK (loss: 10.2).

Shareholders' equity and share capital

Consolidated shareholders' equity at the end of the period amounted to 58.5 MSEK, compared with 61.6MSEK at the end of March 2020.

The number of outstanding shares at the end of the period totaled 58,063,400 and the share capital SEK 4,382,145.83.

At the end of the period, the equity/assets ratio for the Group was 93.6 percent, compared with 94.7 percent at year-end of March 2020.

The share

The company was established on July 13, 2015. Shares in the company have been traded since June 7, 2016 on the Nasdaq First North Growth Market stock exchange with the ticker CYXO. The company's Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, telephone +46 (0)8-503 015 50 and email ca@mangold.se.

Changes in share capital

Year	Event	Increase in share capital (SEK)	Total share capital (SEK)	Change in number of shares	Total number of shares	Quota value (SEK)
2015	Formation of the company	50 000	50 000	500	500	100
2015	Share issue for patent work	450 000	500 000	4 500	5 000	100
2015	Split (1:1 000)	0	500 000	4 995 000	5 000 000	0,1
2016	Split (1000:1 325)	0	500 000	1 625 000	6 625 000	0,075
2016	Share issue	98 113	598 113	1 300 000	7 925 000	0,075
2016	Share issue (First North Listing)	377 358	975 472	5 000 000	12 925 000	0,075
2017	Issue TO1	181 584	1 157 056	2 405 992	15 330 992	0,075
2017	Issue TO2	186 198	1 343 254	2 467 119	17 798 111	0,075
2018	Cash issue	144 632	1 487 886	1 916 372	19 714 483	0,075
2018	Share issue and issue of TO3	1 339 098	2 826 984	17 743 034	37 457 517	0,075
2019	Share issue	877 198	3 704 182	11 622 863	49 080 380	0,075
2020	Share issue	15 266	3 719 448	202 274	49 282 654	0,075
2020	Share issue	16 216	3 735 664	214 858	49 497 512	0,075
2020	Share issue	338 935	4 074 599	4 490 888	53 988 400	0,075
2020	Share issue	307 547	4 382 146	4 075 000	58 063 400	0,075

Organization

The average number of employees during the reporting period was 6 (2), of which the number of employees in the research and development organization accounted for 3 (1). At the end of the period, the Group had 6 employees.

Outlook, including significant risks and uncertainties.

Available liquidity and the capital infusion generated by the directed issues, in combination with income from the existing outstanding warrants are, according to current plans, assumed to be sufficient to finance operations into 2022. Valuation of patents is based on assumptions made about financing and continued operation as a going concern. Unforeseen costs may affect this assessment.

In the case that less funding would be obtained from the warrants, new funding has to be sought or the development plan and timing might need to be adjusted. The possibility of raising external capital may also be affected by powers outside of the company's control, such as fluctuations in the economy or market which may cause it to be more expensive or more difficult to raise new capital. Negative study results or considerable delays may affect the company's possibilities to new financing.

Cyxone's ability to develop pharmaceutical projects to the point at which partnership agreements can be secured, and the partner assumes responsibility for the future development and commercialization of the project, is decisive for the company's long-term financial strength and stability. No partnerships have so far been secured. Negative study results can have a negative impact on the company's ability to attract potential partners. Furthermore, fluctuations in the market or changes in market regulations can affect the company's attractiveness on the market. Cyxone is currently developing three projects in parallel, within three different indications, in an attempt to mitigate this risk and diversify the product portfolio.

A research company such as Cyxone is characterized by high operational and financial risk, since the projects in which the company is involved have both development, regulatory and commercialization risks. In addition, the ability of the company to attract and retain key people with both insights to the field of research, and relevant product development experiences is a significant risk. The company is actively working on improving its possibilities to both

attract and to keep such key personnel. Cyxone has made several recruitments during 2020 to secure that key resources and competencies are available within the company, thereby decreasing the company's dependency on external consultants.

Cyxone is active on an international market which means that the company is affected by exchange rate changes of several different currencies. Cyxone is often reliant on international subcontractors to carry out and execute studies or to produce new materials, as a result of this, fluctuations in exchange rates may have a significant impact on the prices of both goods and services.

Cyxone is active in the field of research and development which entails a risk that results may deviate from expectations, which may have a negative impact on the company in the form of increased costs, delays and reduced opportunities and conditions raising capital or licencing deals. The drug development industry is a highly regulated market with strict regulatory requirements. Cyxone is in several different stages of the development process dependant on obtaining regulatory approval from relevant authorities. The company works within the framework of the regulatory requirements regarding clinical trials and must comply with these rules, but changes in regulatory requirements and processes can affect the company's opportunities to obtain regulatory approval or lead to increased costs and delays in the development process. In brief, the operation is associated with risks related to such factors as pharmaceutical development, competition, advances in technology, patents, regulatory requirements, capital requirements.

The Covid-19 pandemic has a worldwide effect, and it is currently very hard to predict what consequences it will keep having, both short term and long term, for the market or for Cyxone. The Board of Directors and the Management are continuously monitoring the situation closely. If any of the company's activities are deemed to be significantly affected of the Covid-19 pandemic, the company will inform the market. Cyxone is currently conducting a phase 2 clinical trial in Covid-19 patients with the drug candidate Rabeximod. The company has applied for regulatory approval in several different countries in order to minimize and mitigate the risk of individual countries' impact of the pandemic causing a significant risk to the study. The Group's operations are primarily conducted in the Parent Company, which is why risks and uncertainties refer to both the Group and the Parent Company.

Principles for the preparation of this interim report

The group was formed on 30 July 2019 when Cyxone AB formed the subsidiary Cyxone Switzerland AG. The Group reports according to International Financial Reporting Standards (IFRS), as adopted by the EU. See Note 1 Accounting principles.

Condensed consolidated statement of profit or loss

KSEK	Note	Q1, 2021	Q1, 2020
Operating income			
Other income		50	-
Total operating income		50	-
Operating costs			
Other external costs		-5 831	-8 605
Personnel expenses		-2 341	-1 055
Amortisation of intangible assets		-449	-449
Other operating expenses		-41	–
Total operating costs		**-8 662**	**-10 109**
Operating profit/loss		**-8 612**	**-10 109**
Financial income		-	–
Financial costs		-	-88
Net financial items		**-**	**-88**
Profit/loss before tax		**-8 612**	**-10 197**
Tax		-	-
Profit/loss for the period		**-8 612**	**-10 197**
Profit/loss for the period attributable to:			
Parent Company shareholders		-8 612	-10 197
Profit/loss for the period		**-8 612**	**-10 197**
Earnings per share			
Before and after dilution (SEK)		**-0,15**	**-0,21**

Condensed consolidated statement of profit or loss and other comprehensive income

KSEK	Note	Q1, 2021	Q1, 2020
Profit/loss for the period		**-8 612**	**-10 197**
Other comprehensive income			
Items that are or may be reclassified subsequently to profit or loss			
Exchange differences on foreign operations		-	87
		-	87
Other comprehensive income for the period		**-**	**87**
Total comprehensive income for the period		**-8 612**	**-10 110**
Total comprehensive income for the period attributable to			
Parent Company shareholders		-8 612	-10 110
Total comprehensive income for the period		**-8 612**	**-10 110**
The number of outstanding shares at the end of the reporting period			
– Before and after dilution		58 063 400	49 080 380
The average number of outstanding shares at the end of the reporting period			
– Before and after dilution		58 063 400	49 080 380

Condensed consolidated statement of financial position

KSEK	Note	31-mar-21	31-mar-20	31-dec-20
Assets				
Intangible assets		14 407	11 292	14 855
Long-term receivables		19	–	19
Total non-current assets		**14 426**	**11 292**	**14 874**
Trade receivables		–	–	–
Prepaid expenses and accrued income		389	552	543
Other current receivables		399	291	392
Cash and cash equivalents		47 268	52 877	56 343
Total current assets		**48 056**	**53 720**	**57 278**
Total assets		**62 482**	**65 012**	**72 152**
Equity				
Share capital		4 382	3 704	4 382
Other paid in capital		168 410	124 651	168 410
Reserves		-38	88	-38
Retained earnings including profit/loss for the period		-114 261	-66 846	-105 649
Equity attributable to Parent Company shareholders		**58 493**	**61 597**	**67 105**
Total equity		**58 493**	**61 597**	**67 105**
Liabilities				
Trade payables		2 310	2 321	2 577
Other current liabilities		379	120	458
Accrued expenses and deferred income		1 300	974	2 012
Total current liabilities		**3 989**	**3 415**	**5 047**
Total liabilities		**3 989**	**3 415**	**5 047**
Total equity and liabilities		**62 482**	**65 012**	**72 152**

Condensed consolidated statement of changes in equity

KSEK	Equity attributable to the parent company's shareholders				
	Share capital	Other unrestricted equity	Revaluation reserve	Balanced profits incl. The result of the period	Total equity
Opening balance equity 2020-01-01	3 704	124 651	1	-56 649	71 707
Total comprehensive income for the period					
Profit/loss for the period				-10 197	-10 197
Other comprehensive income for the period			87		87
Total comprehensive income for the period			87	-10 197	-10 110
Transactions with the Group's owners					
Share issues					
Total transactions with the Group's owners					
Closing balance equity 2020-03-31	3 704	124 651	88	-66 846	61 597

KSEK	Equity attributable to the parent company's shareholders				
	Share capital	Other unrestricted equity	Revaluation reserve	Balanced profits incl. The result of the period	Total equity
Opening balance equity 2021-01-01	4 382	168 410	-38	-105 649	67 105
Total comprehensive income for the period					
Profit/loss for the period				-8 612	-8 612
Other comprehensive income for the period			-		-
Total comprehensive income for the period			-	-8 612	-8 612
Transactions *with the Group's owners*					
Share issues					
Share-based payments that are settled with equity instruments, IFRS 2					
Total transactions with the Group's owners					
Closing balance equity 2021-03-31	4 382	168 410	-38	-114 261	58 493

Condensed consolidated statement of cash

KSEK	Note	Q1, 2021	Q1, 2020
Operating activities			
Profit/loss before tax		-8 612	-10 197
Adjustment for non-cash items, etc			
Amortisation of intangible assets		449	449
Income tax paid		–	–
		-8 163	-9 748
Increase (-) / Decrease (+) of current receivables		147	745
Increase (-) / Decrease (+) of current liabilities		-1 058	37
Cash flow from operating activities		**-9 074**	**-8 966**
Investing activities			
Cash flow from investing activities		**-**	**-**
Financing activities			
Cash flow from financing activities		**-**	**-**
Total cash flow for the period		-9 074	-8 966
Cash and cash equivalents at the beginning of the period		56 343	61 756
Exchange rate difference in cash and cash equivalents		-1	87
Cash and cash equivalents at the end of the period		**47 268**	**52 877**

There have not been any cash flows from investing and financing activities during the presented periods.

Condensed income statement for the parent company

KSEK	Note	Q1 2021	Q1 2020
Operating income			
Other income		50	-
Total operating income		**50**	**-**
Operating costs			
Other external costs		-5 816	-8 591
Personel costs		-2 341	-1 055
Amortisation of intangible assets		-449	-449
Other operating costs		-41	-
Total operating costs		**-8 647**	**-10 095**
Operating profit/loss		**-8 597**	**-10 095**
Profit/loss from financial items:			
Interest income and similar profit/loss items		-	-
Interest expense and similar profit/loss items		-	-88
Profit/loss before tax		**-8 597**	**-10 183**
Tax		-	-
Profit/loss for the period		**-8 597**	**-10 183**
Earnings per share for the parent company			
Before and after dilution (SEK)		**-0,15**	**-0,21**

Condensed income statement and other comprehensive income for the parent company

KSEK	Note	Q1, 2021	Q1, 2020
Profit/loss for the period		-8 597	-10 183
Total comprehensive income for the period		**-8 597**	**-10 183**

Condensed balance sheet for the Parent company in summary

KSEK	Note	31-mar-21	31-mar-20	31-dec-20
Assets				
Non-current assets				
Intangible assets		14 407	11 292	14 855
Financial assets:				
Participation in group companies		955	955	955
Long-term recievables		19	0	19
Total financial assets		**974**	**955**	**974**
Total non-current assets		**15 381**	**12 247**	**15 829**
Current assets				
Current receivables:				
Trade receivables		-	-	-
Receivables from group companies		99	48	83
Other current receivables		382	549	537
Prepaid expenses and accrued income		399	291	392
Total current receivables		**880**	**888**	**1 012**
Cash and bank		46 344	51 831	55 418
Total current assets		**47 224**	**52 719**	**56 430**
Total assets		**62 605**	**64 966**	**72 259**
Equity and liabilities				
Equity				
Restricted equity				
Share capital		4 382	3 704	4 382
Non-restricted equity				
Share premium reserve		168 410	124 651	168 410
Retained earnings		-105 571	-56 618	-56 618
Profit/loss for the period		-8 597	-10 183	-48 954
Total equity		**58 624**	**61 554**	**67 220**
Current liabilities				
Trade payables		2 306	2 316	2 568
Other current liabilities		379	120	459
Accrued expenses and deferred income		1 296	976	2 012
Total current liabilities		3 981	3 412	5 039
Total equity and liabilities		**62 605**	**64 966**	**72 259**

Notes to the condensed interim financial statements

Note 1 Accounting principles

This quarterly report has been prepared according to the IFRS standards that have been adopted by EU as well as the interpretations of the valid standards adopted by EU, IFRICs. This report for the Group has been prepared according to IAS 34, Interim financial reporting as well as applicable regulations in the Annual Accounts Act. The parent company quarterly report has been prepared according to chapter 9 in the Annual Accounts Act, Quarterly reports and RFR 2, Accounting rules for legal entities. The quarterly report has been prepared for the Group and parent company according to the same accounting principles and conditions applied in the latest Annual Report, except for the amended accounting principles described below.

In addition to the financial reports and their accompanying notes further information according to IAS 34.16A can be found in other sections of the quarterly report.

Note 2 Fair value for financial Instruments

Carrying amount is considered to be a reasonable approximation of fair value for all of the Group's financial instruments.

Auditing

This report has not been reviewed by the company's auditors.

Legal disclaimer

This report contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this report.

Upcoming financial reports and Annual General Meeting

2021

3rd of June	Annual General Meeting
27th of Aug.	Q2 report
12th of Nov.	Q3 report

2022

11th of Feb	Q4 report

The reports will be available from these dates at www.cyxone.com: Cyxone » Financial Reports

Submission of interim report

The interim report for the January – March period 2021 provides a true and fair view of the Parent Company´s and the Group's operations, position and results, and describes significant risks and uncertainties that the Parent Company and Group companies face.

Malmö

May 12, 2021

The Board of Directors

Cyxone AB

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 patients. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Cyxone's Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, telephone +46 (0)8-503 015 50 and email ca@mangold.se. www.cyxone.com